Avanos Medical (NYSE:AVNS – Get Free Report) and Baird Medical Investment (NASDAQ:BDMD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Profitability
This table compares Avanos Medical and Baird Medical Investment’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avanos Medical | -10.40% | 5.47% | 4.05% |
| Baird Medical Investment | N/A | N/A | N/A |
Volatility and Risk
Avanos Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Baird Medical Investment has a beta of -1.41, indicating that its stock price is 241% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avanos Medical | 1 | 1 | 0 | 0 | 1.50 |
| Baird Medical Investment | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 2.3% of Avanos Medical shares are held by company insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Avanos Medical and Baird Medical Investment”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avanos Medical | $701.20 million | 0.90 | -$72.90 million | ($1.58) | -8.62 |
| Baird Medical Investment | N/A | N/A | N/A | N/A | N/A |
Baird Medical Investment has lower revenue, but higher earnings than Avanos Medical.
Summary
Avanos Medical beats Baird Medical Investment on 6 of the 8 factors compared between the two stocks.
About Avanos Medical
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
About Baird Medical Investment
Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.
